=> file caplus

FILE 'CAPLUS' ENTERED AT 12:06:47 ON 24 JAN 2001

FILE COVERS 1967 - 24 Jan 2001 VOL 134 ISS 5
FILE LAST UPDATED: 23 Jan 2001 (20010123/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> d que

L1 STR



G1 O,S,CN

Structure attributes must be viewed using STN Express query preparation.
L3 18 SEA FILE=REGISTRY SSS FUL L1
L4 5 SEA FILE=CAPLUS L3

=> d l4 1-5 ibib abs hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:233800 CAPLUS
DOCUMENT NUMBER: 130:272022
TITLE: Sustained-release tablet formulation to treat Parkinson disease
INVENTOR(S): Ju, Tzu-chi Robert
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916442	A2	19990408	WO 1998-US17992	19980903
WO 9916442	A3	19990617		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9812687	A	20000822	BR 1998-12687	19980303
AU 9892964	A1	19990423	AU 1998-92964	19980903
EP 1017391	A2	20000712	EP 1998-945805	19980903
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FI 2000000720	A	20000329	FI 2000-720	20000329
NO 2000001624	A	20000329	NO 2000-1624	20000329
PRIORITY APPLN. INFO.:			US 1997-60827	19970930
			WO 1998-US17992	19980903

AB A sustained-release tablet which permits twice daily administration for the treatment of Parkinson's disease, comprises (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) 0.3-16 %, starch 60-69 %, and hydroxypropyl Me cellulose 30-40 %.

IT **222415-94-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of methylaminoimidazoquinolinone to treat Parkinson's disease)

RN 222415-94-3 CAPLUS

CN Carbamic acid, methyl[(5R)-1,2,5,6-tetrahydro-1-methoxy-2-oxo-4H-imidazo[4,5,1-ij]quinolin-5-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:603239 CAPLUS
DOCUMENT NUMBER: 127:220605
TITLE: Synthesis of the Selective D2 Receptor Agonist PNU-95666E from D-Phenylalanine Using a Sequential Oxidative Cyclization Strategy
AUTHOR(S): Romero, Arthur G.; Darlington, William H.; McMillan, Moses W.
CORPORATE SOURCE: Medicinal Chemistry Research and Chemical Research Preparations, Pharmacia Upjohn Inc., Kalamazoo, MI, 49001, USA
SOURCE: J. Org. Chem. (1997), 62(19), 6582-6587
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A synthesis of PNU-95666E (I) was developed, starting from D-phenylalanine. Crit. to the success of this synthesis were two oxidative nitrogen annulations to provide the tricyclic ring system. A highly efficient redn. with borane-dimethyl sulfide was used to reduce three different functional groups, a total of six hydrides transferred, with no concomitant racemization, contributing to the synthesis of I in eight steps with an overall yield of 26%. The utility of this synthetic route has been demonstrated by the completion this synthesis on the multikilogram scale.

IT **194222-96-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of PNU-95666E)
RN 194222-96-3 CAPLUS
CN Carbamic acid, methyl(1,2,5,6-tetrahydro-1-methoxy-2,4-dioxo-4H-

imidazo[4,5,1-ij]quinolin-5-yl)-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:539253 CAPLUS
DOCUMENT NUMBER: 127:190739
TITLE: Preparation of 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-ones having central nervous system activity
INVENTOR(S): Romero, Arthur G.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA
SOURCE: U.S., 10 pp. Cont.-in-part of U.S. Ser. No. 97,608, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5652245	A	19970729	US 1996-592328	19960123
WO 9504056	A1	19950209	WO 1994-US6648	19940617

W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 1993-97608	19930727
	WO 1994-US6648	19940617

OTHER SOURCE(S): MARPAT 127:190739
GI



AB The title compds. [I; R1, R2 = H, C1-6 alkyl; R1R2 = pyrrolidine, piperidine, morpholine, imidazole; X = MeO, R3SO2, CF3SO2, CN; R3 = C1-6 alkyl, (un)substituted C5-10 arom. ring; Y = H, Cl, Br, F, CN, etc.] and their salts , having anxiolytic, anti-depressant and central nervous system activity, and useful for treating schizophrenia, Parkinson's disease, anxiety, depression, migraine or for lowering blood pressure, were prepd. For example, 7-step synthesis of compd. I [R1 = H; R2 = nPr; X = MeO; Y = H] starting from (R)-1,2,3,4-tetrahydro-1-methoxy-2-oxo-3-quinolinamine is described. Treatment of above mentioned compd. I [R1 = H; R2 = nPr; X = MeO; Y = H] with 1-iodopropane in the presence of K2CO3 in MeCN afforded 90% I [R1 = R2 = nPr; X = MeO; Y = H] which showed Ki of 38 nM against 5-HT1DB receptor binding.

IT **166742-81-0P 166742-92-3P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-ones having central nervous system activity)

RN 166742-81-0 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(methylamino)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-92-3 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(propylamino)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **166742-82-1P 166742-83-2P 166742-84-3P**
166742-93-4P 166742-94-5P 166742-95-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-ones having central nervous system activity)
RN 166742-82-1 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(methylamino)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-83-2 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dimethylamino)-5,6-dihydro-1-methoxy-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-84-3 CAPLUS

CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dimethylamino)-5,6-dihydro-1-methoxy-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(propylamino)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-1-methoxy-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-95-6 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-1-methoxy-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT **194222-72-5P 194222-88-3P 194222-96-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-ones having central nervous system activity)
RN 194222-72-5 CAPLUS
CN Acetamide, 2,2,2-trifluoro-N-methyl-N-(1,2,5,6-tetrahydro-1-methoxy-2,4-dioxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 194222-88-3 CAPLUS
CN Acetamide, 2,2,2-trifluoro-N-propyl-N-(1,2,5,6-tetrahydro-1-methoxy-2,4-dioxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194222-96-3 CAPLUS
CN Carbamic acid, methyl(1,2,5,6-tetrahydro-1-methoxy-2,4-dioxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:213416 CAPLUS
DOCUMENT NUMBER: 124:343186
TITLE: Oxidative cyclization of acyclic ureas with bis(trifluoroacetoxy)iodobenzene to generate N-substituted 2-benzimidazolinones
AUTHOR(S): Romero, Arthur G.; Darlington, William H.; Jacobsen, E. Jon; Mickelson, John W.
CORPORATE SOURCE: Med. Chem. Res., Pharmacia, Upjohn, Inc., Kalamazoo, MI, 49001, USA
SOURCE: Tetrahedron Lett. (1996), 37(14), 2361-4
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:343186
GI



I



II

AB A facile method to synthesize N-substituted 2-benzimidazolinones from secondary arom. amines is presented. Sequential treatment of a secondary arom. amine with phosgene and methoxylamine afforded an acyclic 3-substituted 3-aryl-1-methoxyurea. Brief exposure of this urea to bis(trifluoroacetoxy)iodobenzene induced an oxidative cyclization. to the ortho-position of the benzene ring, resulting in the formation of a 3-substituted 1-methoxy-2-benzimidazolinone, e.g. I and II. Hydrogenation over Pd/C cleaves the methoxy group to afford the N-substituted 2-benzimidazolinone.

IT **176790-85-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(oxidative cyclization of acyclic ureas with bis(trifluoroacetoxy)iodobenzene to generate N-substituted 2-benzimidazolinones)

RN 176790-85-5 CAPLUS

CN Carbamic acid, propyl(1,2,5,6-tetrahydro-1-methoxy-2-oxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1995:750538 CAPLUS
DOCUMENT NUMBER: 123:143891
TITLE: Heterocyclic amines having central nervous system activity
INVENTOR(S): Romero, Arthur G.
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9504056	A1	19950209	WO 1994-US6648	19940617
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2166700	AA	19950209	CA 1994-2166700	19940617
AU 9472461	A1	19950228	AU 1994-72461	19940617
AU 684808	B2	19980108		
EP 724584	A1	19960807	EP 1994-921952	19940617
EP 724584	B1	19971105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09500898	T2	19970128	JP 1994-505808	19940617
AT 159943	E	19971115	AT 1994-921952	19940617
ES 2108474	T3	19971216	ES 1994-921952	19940617
CN 1128030	A	19960731	CN 1994-192910	19940627
CN 1043574	B	19990609		
US 5652245	A	19970729	US 1996-592328	19960123
PRIORITY APPLN. INFO.:			US 1993-97608	19930727
			WO 1994-US6648	19940617

OTHER SOURCE(S): MARPAT 123:143891
GI



I



II



III

AB Tricyclic N-contg. compds. I, having CNS (anxiolytic and anti-depressant) activity, and pharmaceutical salts thereof, are claimed [wherein R1, R2 = independently H, C1-6 alkyl; or R1R2 = atoms to form pyrrolidine, piperidine, morpholine or imidazole; X = OMe, SO2R3, SO2CF3 or CN; R3 = C1-6 alkyl or aryl; Y = H, Cl, Br, F, CN, CONR1R2, CF3, OMe, SO2NR1R2].

I

are said to be suitable for treating schizophrenia, Parkinson's disease, anxiety, depression, high blood pressure, or migraine. Four compds. and their HCl salts were prepd. For example,
(R)-1,2,3,4-tetrahydro-1-methoxy-
2-oxo-3-quinolinamine underwent a sequence of N-acylation of the pendant amino group with ClCO2Me (99%), borane redn. of the oxo group and the carbamate (100%), double N-acylation (ring and methylamino nitrogens) with
trifluoroacetic anhydride (67%), and selective hydrolysis of the ring trifluoroacetyl group (100%), to give the intermediate II. Treatment of II with phosgene and then methoxylamine-HCl in the presence of Et3N gave 75% 1-methoxyaminocarbonyl deriv., which was cyclized by treatment with PhI(OCOCF3) (72%) and deprotected with K2CO3 in MeOH (100%) to give title compd. III. In an isolation-induced aggression assay in mice, III (oral, dose unspecified) increased latency to attack from 66 s (control) to 600 s. Addnl. 5-HT receptor data for another I showed selectivity for 5-HT1DB
receptors, with activity residing in the (R)-isomer.

IT **166743-02-8**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(bioactivity; prepn. of aminoimidazoquinolinones with 5-HT1 activity)
RN 166743-02-8 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-1-methoxy-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **166941-54-4 166941-55-5**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioactivity; prepn. of aminoimidazoquinolinones with 5-HT1 activity)
RN 166941-54-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dimethylamino)-5,6-dihydro-1-methoxy- (9CI) (CA INDEX NAME)



RN 166941-55-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-1-methoxy- (9CI) (CA INDEX NAME)



IT **166742-80-9P 166742-91-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(intermediate; prepn. of aminoimidazoquinolinones with 5-HT1 activity)
RN 166742-80-9 CAPLUS
CN Acetamide,
2,2,2-trifluoro-N-methyl-N-(1,2,5,6-tetrahydro-1-methoxy-2-oxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166742-91-2 CAPLUS
CN Acetamide,
2,2,2-trifluoro-N-propyl-N-(1,2,5,6-tetrahydro-1-methoxy-2-oxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **166742-81-0P 166742-92-3P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminoimidazoquinolinones with 5-HT1 activity)
RN 166742-81-0 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(methylamino)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-92-3 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(propylamino)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **166742-82-1P 166742-83-2P 166742-84-3P**
166742-93-4P 166742-94-5P 166742-95-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminoimidazoquinolinones with 5-HT1 activity)
RN 166742-82-1 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(methylamino)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-83-2 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dimethylamino)-5,6-dihydro-1-methoxy-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-84-3 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dimethylamino)-5,6-dihydro-1-methoxy-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-93-4 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(propylamino)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-94-5 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-1-methoxy-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-95-6 CAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-1-methoxy-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 12:08:01 ON 24 JAN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 23 Jan 2001 (20010123/PD)
FILE LAST UPDATED: 23 Jan 2001 (20010123/ED)
HIGHEST PATENT NUMBER: US6178551
CA INDEXING IS CURRENT THROUGH 23 Jan 2001 (20010123/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 23 Jan 2001 (20010123/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Sep 2000
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Sep 2000

>>> Page images are available for patents from 1/1/1997. Current <<<
>>> week patent text is typically loaded by Thursday morning and <<<
>>> page images are available for display by the end of the day. <<<
>>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records. A thesaurus is available for the <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<
>>> fields. This thesaurus includes catchword terms from the <<<
>>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<
>>> available for the WIPO International Patent Classification <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<
>>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<
>>> the /IC5 and /IC fields include the corresponding catchword <<<
>>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d que

L1 STR



G1 O,S,CN

Structure attributes must be viewed using STN Express query preparation.
L3 18 SEA FILE=REGISTRY SSS FUL L1
L5 1 SEA FILE=USPATFULL L3

=> d l5 ibib abs htistr

'HTISTR' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
ENTER DISPLAY FORMAT (STD):ibib ans hitstr

'ANS' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
ENTER DISPLAY FORMAT (STD):end

=> d l5 ibib abs hitstr

L5 ANSWER 1 OF 1 USPATFULL

ACCESSION NUMBER:	97:66132 USPATFULL		
TITLE:	Heterocyclic amines having central nervous system activity		
INVENTOR(S):	Romero, Arthur G., Kalamazoo, MI, United States		
PATENT ASSIGNEE(S):	Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)		
	NUMBER	DATE	
PATENT INFORMATION:	US 5652245	19970729	
	WO 9504056	19950209	
APPLICATION INFO.:	US 1996-592328	19960123	(8)
	WO 1994-US6648	19940617	
		19960123	PCT 371 date
		19960123	PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-97608, filed on 27 Jul 1993, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Morris, Patricia L.		
LEGAL REPRESENTATIVE:	Corneglio, Donald L.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	832		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Tricyclic nitrogen containing compounds, having anxiolytic and anti-depressant activity and central nervous system activity of the following structural formula: ##STR1## and pharmaceutically acceptable salts thereof wherein R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl or R.sub.1 and R.sub.2 are joined to form pyrrolidine, piperidine, morpholine or imidazole. X is OCH.sub.3, SO.sub.2 R.sub.3, SO.sub.2 CF.sub.3 or CN where R.sub.3 is C.sub.1-6 alkyl or an Aryl; and

Y is hydrogen, Cl, Br, F, CN, CONR.sub.1 R.sub.2, CF.sub.3, OCH.sub.3, SO.sub.2 NR.sub.1 R.sub.2. These new compounds are suitable for treating anxiolytic disorder, schizophrenia, Parkinson's disease, anxiety, depression or as compounds for lowering blood pressure or treating migraine headaches in patients in need of such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **166742-81-0P 166742-92-3P**
(prepn. of 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-ones having central nervous system activity)

RN 166742-81-0 USPATFULL

CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(methylamino)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-92-3 USPATFULL
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(propylamino)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **166742-82-1P 166742-83-2P 166742-84-3P**
166742-93-4P 166742-94-5P 166742-95-6P
(prepn. of 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-ones having central nervous system activity)
RN 166742-82-1 USPATFULL
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(methylamino)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-83-2 USPATFULL
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dimethylamino)-5,6-dihydro-1-methoxy-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-84-3 USPATFULL
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dimethylamino)-5,6-dihydro-1-methoxy-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-93-4 USPATFULL
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-1-methoxy-5-(propylamino)-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 166742-94-5 USPATFULL
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-1-methoxy-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166742-95-6 USPATFULL
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-1-methoxy-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

IT **194222-72-5P 194222-88-3P 194222-96-3P**
(prepn. of 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-ones having central nervous system activity)
RN 194222-72-5 USPATFULL
CN Acetamide, 2,2,2-trifluoro-N-methyl-N-(1,2,5,6-tetrahydro-1-methoxy-2,4-dioxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 194222-88-3 USPATFULL
CN Acetamide, 2,2,2-trifluoro-N-propyl-N-(1,2,5,6-tetrahydro-1-methoxy-2,4-

dioxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 194222-96-3 USPATFULL
CN Carbamic acid, methyl(1,2,5,6-tetrahydro-1-methoxy-2,4-dioxo-4H-imidazo[4,5,1-ij]quinolin-5-yl)-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).